Nicergoline


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Peripheral vascular disease; Mental deterioration associated w/ cerebrovascular insufficiency 10 mg 3 times/day. Maintenance: 5-10 mg 3 times/day. Max: 60 mg/day in divided doses. IV Peripheral vascular disease; Mental deterioration associated w/ cerebrovascular insufficiency 4-8 mg via infusion. IM Peripheral vascular disease; Mental deterioration associated w/ cerebrovascular insufficiency 2-4 mg twice daily.
Dosage Details
Intramuscular
Peripheral vascular disease, Symptoms of mental deterioration associated with cerebrovascular insufficiency
Adult: 2-4 mg bid.

Intravenous
Peripheral vascular disease, Symptoms of mental deterioration associated with cerebrovascular insufficiency
Adult: 4-8 mg by slow IV infusion (over 30 min).

Oral
Mental deterioration associated with cerebrovascular insufficiency, Peripheral vascular disease
Adult: 10 mg tid. Maintenance: 5-10 mg tid. Max: Up to 60 mg daily in divided doses.
Renal Impairment
Reduce dose.
Administration
Should be taken on an empty stomach.
Reconstitution
Intravenous:
Dilute in 250 ml saline solution.
Special Precautions
Porphyria. Pregnancy.
Adverse Reactions
GI disturbances; hypotension (especially after parenteral admin). Hot flushes, malaise, hyperacidity, nausea, diarrhoea, dizziness, somnolence.
Drug Interactions
May potentiate action of antihypertensives. May increase cardiac depressant effects of propranolol.
Action
Description: Nicergoline is an ergot derivative. It has α-adrenergic blocking activity and produces vasodilatation.
Onset: 1-1.5 hr (oral).
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract (oral).
Distribution: Protein-binding: 82-87%.
Metabolism: Undergoes significant 1st-pass effect.
Excretion: Via urine (80%), via faeces (20%).
Disclaimer: This information is independently developed by MIMS based on Nicergoline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in